ROCHESTER, Minn. — Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers.
“Five years ago, the survival rate for people with blood cancers was 10% to 15%. Nowadays, we are seeing a survival rate of 40%. The job is not done yet,” says Mohamed Kharfan Dabaja, M.D., a hematologist and director of blood marrow and transplantation and cellular therapies at Mayo Clinic
